ABUS vs. RXRX, CPRX, KNSA, OGN, ALVO, CNTA, IBRX, TARS, OCUL, and AGIO
Should you be buying Arbutus Biopharma stock or one of its competitors? The main competitors of Arbutus Biopharma include Recursion Pharmaceuticals (RXRX), Catalyst Pharmaceuticals (CPRX), Kiniksa Pharmaceuticals International (KNSA), Organon & Co. (OGN), Alvotech (ALVO), Centessa Pharmaceuticals (CNTA), ImmunityBio (IBRX), Tarsus Pharmaceuticals (TARS), Ocular Therapeutix (OCUL), and Agios Pharmaceuticals (AGIO). These companies are all part of the "pharmaceutical products" industry.
Arbutus Biopharma vs. Its Competitors
Recursion Pharmaceuticals (NASDAQ:RXRX) and Arbutus Biopharma (NASDAQ:ABUS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.
Arbutus Biopharma has a net margin of -352.24% compared to Recursion Pharmaceuticals' net margin of -1,004.91%. Arbutus Biopharma's return on equity of -59.28% beat Recursion Pharmaceuticals' return on equity.
89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are owned by institutional investors. 8.4% of Recursion Pharmaceuticals shares are owned by insiders. Comparatively, 20.3% of Arbutus Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Recursion Pharmaceuticals currently has a consensus price target of $7.00, indicating a potential upside of 43.30%. Arbutus Biopharma has a consensus price target of $5.50, indicating a potential upside of 51.72%. Given Arbutus Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Arbutus Biopharma is more favorable than Recursion Pharmaceuticals.
In the previous week, Recursion Pharmaceuticals had 8 more articles in the media than Arbutus Biopharma. MarketBeat recorded 11 mentions for Recursion Pharmaceuticals and 3 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.40 beat Recursion Pharmaceuticals' score of 0.87 indicating that Arbutus Biopharma is being referred to more favorably in the news media.
Recursion Pharmaceuticals has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500. Comparatively, Arbutus Biopharma has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.
Arbutus Biopharma has lower revenue, but higher earnings than Recursion Pharmaceuticals. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Arbutus Biopharma beats Recursion Pharmaceuticals on 11 of the 16 factors compared between the two stocks.
Get Arbutus Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ABUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arbutus Biopharma Competitors List
Related Companies and Tools
This page (NASDAQ:ABUS) was last updated on 8/28/2025 by MarketBeat.com Staff
MarketBeat All Access